FN1 and prostate carcinoma: Clinical evidences indicated that tumor-associated FN (also termed oncofetal FN), is overexpressed in many malignant cancers, including breast cancer (Ioachim et al., 2002; Bae et al., 2013), prostate cancer (Suer et al., 1996; Albrecht et al., 1999), bladder cancer (Arnold et al., 2016), oral squamous cell carcinoma (Lyons et al., 2001), head and neck squamous cell carcinoma (Mhawech et al., 2005), colorectal cancer (Inufusa et al., 1995) and lung cancer (Khan et al., 2005), and upregulated FN expression has been correlated with poor prognosis of the patients.